



Technical Report No. 81

Cell-Based Therapy Control Strategy



PDA Cell-Based Therapy Control Strategy Technical Report Team

Authors

Valérie Pimpaneau , Voisin Consulting, Co-Chair	Margit Jeschke , PhD, Novartis
Jean Stanton , Johnson and Johnson., Co-Chair	Michele Myers , PhD, GlaxoSmithKline
Michael Blackton , Adaptimmune LLC	Audra Riley , NewLink Genetics
Vijay Chiruvolu , PhD, Kite Pharma	Mercedes Segura , Ph.D., bluebird bio
Fabio D'Agostino , PhD, Newcastle University	

Contributors

Richard Dennett , Voisin Consulting	Maria del Pilar Redondo , TiGenix
Ricardo Jimenez , Lonza Houston, Inc.	Kirstin Powel , Novartis
Bernadette Keane , PhD, Keane Consulting	Karen Walker , Seattle Genetics
Mark Leney , PhD, ClearPath Development Company	

To order this document, please visit: go.pda.org/TR81

Cell-Based Therapy Control Strategy

Technical Report No. 81

ISBN: 978-1-945584-06-0

© 2018 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 Introduction.....	1	7.0 CONTROL STRATEGY	25
1.1 Scope and Purpose	2	7.1 Process Parameters Controls.....	26
1.2 Background.....	3	7.2 Material Attribute Controls.....	27
2.0 Glossary and Abbreviations	5	7.2.1 Raw Materials	27
2.1 Abbreviations.....	5	7.2.2 Primary Cells as Starting Materials.....	28
3.0 Product Profile	5	7.2.2.1 Vectors as Starting Materials	29
3.1 Target Product Profile.....	5	7.2.3 Components.....	29
3.2 Quality Target Product Profile.....	7	7.3 Procedural Controls	30
3.3 TPP and QTPP for A-CeT.....	8	7.3.1 Aseptic Manual Processing.....	30
4.0 Critical Quality Attributes.....	10	7.3.2 Personnel.....	30
4.1 Criticality Assessment	11	7.3.3 Environmental Monitoring.....	31
4.2 CQAs for A-CeT.....	12	7.3.4 Facilities and Equipment	32
4.2.1 Visual Appearance.....	12	7.3.5 Advantages to Using Isolators	
4.2.2 Identity	12	and Automation	32
4.2.3 Impurities	14	7.4 Testing Controls	32
4.2.4 Potency.....	14	7.4.1 Product Release Specification	33
4.2.5 Strength/Dose.....	14	7.4.1.1 Identity.....	33
4.2.6 Safety.....	14	7.4.1.2 Potency	33
5.0 Critical Process Parameters	15	7.4.1.3 Purity.....	34
5.1 Identification of Process Parameters (Step 1)	15	7.4.1.4 Safety	34
5.1.1 Process Mapping for A-CeT	15	7.4.1.5 Dose	35
5.2 Parameter Criticality Assessment (Step 2).....	17	7.4.2 In-Process Testing.....	35
5.2.1 Parameter Criticality Assessment for A-CeT ...	17	7.4.3 Characterization.....	36
5.3 Parameter Risk (or Process Capability)		7.4.4 Process Monitoring.....	37
Assessment (Step 3).....	19	7.5 A-CeT Manufacturing Control Strategy	37
5.3.1 Process Capability Assessment for A-CeT	20	7.5.1 Control Strategy Summary for A-CeT	42
5.4 Process Performance Assessment.....	20	7.5.1.1 Material Attribute Controls for A-CeT	42
6.0 Critical Material Attributes.....	21	7.5.1.2 Procedural Controls for A-CeT.....	43
6.1 Identification of Raw Materials (Step 1)	21	7.5.1.3 Process Parameter Controls for A-CeT.....	43
6.2 Criticality Assessment (Step 2)	22	8.0 Lifecycle Management	44
6.3 Raw Material Risk (or Process Capability)		9.0 Summary	44
Assessment (Step 3).....	23	10.0 References	46

FIGURES AND TABLES INDEX

Figure 1.0-1	Process Flow Diagram for A-CeT	2	Table 6.2-1	Raw Materials Impact Classification.....	22
Table 3.1-1	Points to Consider for the Development of the TPP	6	Table 6.2-2	Process Reagents Criticality Assessment of Culture Expansion Step on A-CeT CQAs ...	23
Table 3.2-1	Points to Consider for QTPPs.....	8	Table 6.3-1	Occurrence Scoring for Raw Materials.....	24
Table 3.3-1	Sample TPP for A-CeT.....	9	Table 6.3-2	Detection Scoring for Raw Materials	24
Table 3.3-2	Sample QTPP for A-CeT	9	Table 6.3-3	Quantitative Impact of Process Reagents for Culture Expansion Step on A-CeT CQAs..	25
Table 4.1-1	Impact (Severity) Assessment.....	12	Figure 7.0-1	Schematic Control Strategy Development..	26
Table 4.1-2	Criteria for Uncertainty Scoring of Product Attributes	12	Figure 7.0-2	Specific Elements of Control Strategy Components	26
Table 4.1-3	Product Attribute Criticality Assessment....	12	Figure 7.3.3-1	Foundation for Environmental Monitoring Programs.....	31
Table 4.2.3-1	Example Criticality Assessment Results for A-CeT.....	13	Table 7.4.3-1	Examples of Characterization Testing.....	36
Table 5.1.1-1	IPO Diagram for A-CeT Cell Culture Expansion Step	16	Table 7.5-1	Implementation of Risk-based Tools for A-CeT	38
Table 5.2-1	Process Parameter Severity Scoring	17	Figure 7.5-1	Decision Tree for Parameter or Material Criticality Assessment (PMCA)	38
Table 5.2.1-1	Parameter Criticality Assessment for Culture Expansion Step of A-CeT CQAs.....	18	Figure 7.5-2	Decision Tree for Parameter Capability Assessment.....	38
Table 5.3-1	Criteria for Occurrence Assessment	19	Table 7.5-2	Example of Elements of the A-CET Control Strategy for Safety CQA.....	39
Table 5.3-2	Criteria for Detection Assessment	19	Table 7.5-3	Testing Plan for A-CeT	42
Table 5.3.1-1	Quantitative Impact Process Parameters of Culture Expansion Step on A-CeT CQAs	20	Figure 9.0-1	Overarching Strategy for Risk-based Approach	45
Figure 6.0-1	Assessments Required to Contribute to Overall Raw Material Control Strategy	21	Figure 9.0-2	Control Strategy for Critical Quality Attributes	45
Figure 6.1-1	Materials Used in the Manufacturing of an Autologous Cartilage Cell Product.....	22			